Impact BioMedical Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $38.3M
- Price
- $4.48
- % Change (Daily % change from the live per-ticker quote feed.)
- -4.27%
- Volume
- 10.7K
About
Houston, Texas-based Impact BioMedical Inc., founded in 2018, focuses on discovering and developing innovative products and therapeutic options for both specialty biopharmaceuticals and consumer healthcare markets. The company features several key technologies: its "Linebacker" platform utilizes small molecule electrophilically enhanced polyphenol compounds with potential applications in treating cancer, inflammatory diseases, and neurological conditions. Additionally, "Laetose" technology, a unique blend of sugar and inositol, is designed to counteract the inflammatory and metabolic responses usually triggered by sugar consumption. Impact BioMedical also creates "functional fragrance formulations," which are a series of fragrances incorporating specialized botanical ingredients for antimicrobial purposes, or as active additives in items like insect repellents, cleaning products, personal care items, and fabrics. Rounding out its offerings is the "Equivir/Equivir G" technology, a distinctive mix of polyphenols that has exhibited antiviral properties, suitable for use in health supplements and medications.
Quick stats
Shares outstanding8.5M
Computed float—
Float / sharesUnknown
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001834105
AI Summary
AI-generated1/8
minorbullishm and a
DSS, Inc. Announces Form F-4 Filing in Connection with Impact Biomedical’s Proposed Business Combination with Zoar Limited
DSS, Inc. announced that Zoar Limited has filed a Form F-4 registration statement with the SEC in connection with Impact Biomedical's proposed business combination with Zoar.
DSS is a significant stockholder of Impact Biomedical (NYSE American: IBO), and CEO Jason Grady characterized the filing as continued momentum that could ultimately create meaningful value for DSS and its shareholders.
Completion remains contingent on the SEC declaring the registration statement effective, Impact stockholder approval, and NYSE American listing of Zoar ordinary shares, so the transaction and any value to DSS are not assured.
Red flags
- Registration Statement not yet effective; SEC review is ongoing
- Deal completion contingent on Impact stockholder approval and NYSE American listing of Zoar ordinary shares
- No transaction valuation, consideration mix, or size of DSS's stake in Impact disclosed in the release